TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11920488

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (40 mg genistein per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10798812

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 8844237

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 20
Study: 9259823

Group type: EXPERIMENTAL
Intervention: 0.5 CPD‐A2 RCC
Number of subjects: 49

Group type: COMPARATOR
Intervention: CPD‐A1 RCC
Number of subjects: 49
Study: 6669927

Group type: EXPERIMENTAL
Intervention: Instilled fluid volumes of 2.5, 5, 10, and 15 ml at pH 1.0, 4.0, or 7.0
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Instilled fluid at low pH (1.0)
Number of subjects: 8
Study: 31843854

Group type: EXPERIMENTAL
Intervention: HealthTracker-based structured medication review tool
Number of subjects: 79
Study: 30339644

Group type: EXPERIMENTAL
Intervention: PC‐PALs
Number of subjects: 190

Group type: COMPARATOR
Intervention: GP‐PALs
Number of subjects: 190
Study: 26332775

Group type: EXPERIMENTAL
Intervention: 105RM
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 125RM
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0RM
Number of subjects: 14
Study: 26252038

Group type: EXPERIMENTAL
Intervention: Inferior meatal antrostomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: No inferior meatal antrostomy (control group)
Number of subjects: 44
Study: 22565284

Group type: EXPERIMENTAL
Intervention: CCCL ALL protocol (risk-adapted therapy)
Number of subjects: 111
Study: 20128938

Group type: EXPERIMENTAL
Intervention: diet/probiotics
Number of subjects: 256

Group type: COMPARATOR
Intervention: diet/placebo
Number of subjects: 256

Group type: COMPARATOR
Intervention: control
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: diet intervention
Number of subjects: 256
Study: 18926146

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15743283

Group type: EXPERIMENTAL
Intervention: Agility exercise group (n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Stretching/weight-shifting exercise group (n=31)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Agility and Stretching/weight-shifting)
Number of subjects: 61
Study: 11924899

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 27
Study: 10090111

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, Clonidine, Atenolol
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 7750020

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU/day i.m. plus 500 mg of elemental calcium for 10 days each month)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Elemental calcium (500 mg for 10 days each month)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 72
Study: 2105985

Group type: EXPERIMENTAL
Intervention: Ketorolac 2% gel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Etofenamate
Number of subjects: 37
Study: 7041813

Group type: EXPERIMENTAL
Intervention: Cefonicid, 1 g daily (21 cases)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cefamandole, 1 g every 6 h (12 cases)
Number of subjects: 33
Study: 31663620

Group type: EXPERIMENTAL
Intervention: DOX–MNPs treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avasimibe combined with DOX–MNPs treatment
Number of subjects: 0
Study: 30842881

Group type: EXPERIMENTAL
Intervention: Participatory Community-Based Health Information System (PCBHIS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison area (no PCBHIS)
Number of subjects: 10
Study: 28009106

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (high dose 1010 CFU/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (low dose 108 CFU/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 25591799

Group type: EXPERIMENTAL
Intervention: Tivozanib 0.5 mg with mFOLFOX-6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg with mFOLFOX-6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tivozanib with mFOLFOX-6
Number of subjects: 30
Study: 25618969

Group type: EXPERIMENTAL
Intervention: Xinfeng capsules (XFC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Salazopyrin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 120
Study: 21094015

Group type: EXPERIMENTAL
Intervention: Web-based module
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 141
Study: 19785675

Group type: EXPERIMENTAL
Intervention: Training in depression for intervention pharmacists
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care for control pharmacists
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General outcomes for all pharmacists
Number of subjects: 32
Study: 20888887

Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16299430

Group type: EXPERIMENTAL
Intervention: Functional Status Indicators (FSI)
Number of subjects: 6465

Group type: COMPARATOR
Intervention: Comorbidity indices
Number of subjects: 6465
Study: 12117024

Group type: EXPERIMENTAL
Intervention: Multiple ligation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Single ligation
Number of subjects: 109
Study: 10430010

Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring
Number of subjects: 303

Group type: COMPARATOR
Intervention: Estriol suppositories
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 303
Study: 8520033

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg b.i.d. per os)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Itraconazole (100 mg b.i.d. per os)
Number of subjects: 120
Study: 2097908

Group type: EXPERIMENTAL
Intervention: Midazolam 0.35 mg/kg (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 0.45 mg/kg (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 7439520

Group type: EXPERIMENTAL
Intervention: 2% sodium fusidate ointment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 2% fusidic acid cream
Number of subjects: 101
Study: 27341089

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua MFCL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua SV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PureVision MFCL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proclear D (center-distance MFCL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-Vision (SV) lens
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All lens types
Number of subjects: 40
Study: 27216274

Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab
Number of subjects: 561

Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide, and rituximab
Number of subjects: 561
Study: 23991719

Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (A group, n = 58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (VR group, n = 58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (VR group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (A group)
Number of subjects: 116
Study: 22082301

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 46)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 94
Study: 20361381

Group type: EXPERIMENTAL
Intervention: Pediatric granule formulation of artesunate-mefloquine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Co-blister tablet formulation
Number of subjects: 71
Study: 18721455

Group type: EXPERIMENTAL
Intervention: Early shockroom CT scanning
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Standard diagnostic imaging strategy
Number of subjects: 1124
Study: 16356228

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose between 80 and 110 mg/dl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin therapy (blood glucose less than 200 mg/dl)
Number of subjects: 0
Study: 12421159

Group type: EXPERIMENTAL
Intervention: 100% oxygen (HBO treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10% oxygen in nitrogen (hyperbaric normoxic placebo = sham treatment)
Number of subjects: 16
Study: 10601381

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days, n = 19,939)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo (n = 19,937)
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days) among smokers
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo among smokers
Number of subjects: 39876
Study: 7723496

Group type: EXPERIMENTAL
Intervention: 3.85% carmustine polymer discs
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo polymer discs
Number of subjects: 222
Study: 2104115

Group type: EXPERIMENTAL
Intervention: Vaccination offered through a questionnaire (first period)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Vaccination offered without questionnaire (second period)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (third period)
Number of subjects: 298
Study: 6996113

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (60 mg elemental iron)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (60 mg elemental iron) with riboflavin (6mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 101
Study: 31125164

Group type: EXPERIMENTAL
Intervention: Chewing gum (long-term group, 19 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chewing gum (short-term group, 7 days)
Number of subjects: 100
Study: 29358012

Group type: EXPERIMENTAL
Intervention: Once-daily eliglustat dosing
Number of subjects: 170

Group type: COMPARATOR
Intervention: Twice-daily eliglustat dosing
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both dosing regimens
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Once-daily and twice-daily dosing
Number of subjects: 170
Study: 27488042

Group type: EXPERIMENTAL
Intervention: Regular powder (RP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dust-free bleaching powder (DFP)
Number of subjects: 12
Study: 24673517

Group type: EXPERIMENTAL
Intervention: Ipswich Touch Test
Number of subjects: 331

Group type: COMPARATOR
Intervention: 10-g monofilament testing
Number of subjects: 331
Study: 21841525

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of periaqueductal grey
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of subthalamic nucleus
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control nuclei stimulation (sensory thalamus and globus pallidus interna)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation overall
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Changes in thoracic diameter
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 second
Number of subjects: 37
Study: 20381162

Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High-density negative ions
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dim red light
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low-density negative ions
Number of subjects: 73
Study: 18445980

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus alpha-tocopherol supplementation (400 IU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone (6000 cGy in five fractions per week for 6 weeks)
Number of subjects: 0
Study: 15897788

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/d
Number of subjects: 96

Group type: COMPARATOR
Intervention: Irbesartan 300 mg/d
Number of subjects: 96
Study: 12370460

Group type: EXPERIMENTAL
Intervention: IV glucose infusion
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral glucose
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: COMPARATOR
Intervention: IV glucose in healthy subjects
Number of subjects: 5
Study: 9843903

Group type: EXPERIMENTAL
Intervention: L-NAME 1 microg. kg‐1. min‐1 for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-NAME 5 microg. kg‐1. min‐1 for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-NAME 25 microg. kg‐1. min‐1 for 30 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7598322

Group type: EXPERIMENTAL
Intervention: Self palpation and mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preservative therapy (QUART)
Number of subjects: 0
Study: 2606014

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tinidazole (Fasigyn)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic Metronidazole (Metrozol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic Tinidazole (Tynazole)
Number of subjects: 0
Study: 1122668

Group type: EXPERIMENTAL
Intervention: Deltoid muscle blood flow (MBF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gluteus muscle blood flow (MBF)
Number of subjects: 20
Study: 29310548

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy focusing on interpersonal mechanisms of change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28383947

Group type: EXPERIMENTAL
Intervention: TBI factsheet
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Personal stories of people with TBI
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 26109111

Group type: EXPERIMENTAL
Intervention: Multicomponent audit and feedback intervention delivered by telephone and email, consisting of 2-4 canteen menu audits over 12 months.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual support (control group).
Number of subjects: 72
Study: 23829646

Group type: EXPERIMENTAL
Intervention: Football training 2x1 h · week(‐1) for 16 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Elite trained (ET)
Number of subjects: 27
Study: 22364067

Group type: EXPERIMENTAL
Intervention: Cultural competency training and race-stratified performance reports
Number of subjects: 17
Study: 19857446

Group type: EXPERIMENTAL
Intervention: Lower dose (LD) of vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher dose (HD) of vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16918564

Group type: EXPERIMENTAL
Intervention: Bleomycin tattoo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cryotherapy combined with intralesional triamcinolon injection
Number of subjects: 45
Study: 15579914

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg/d
Number of subjects: 0
Study: 11360530

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Yin Meridians
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group treated at Yang Meridians
Number of subjects: 45
Study: 9564292

Group type: EXPERIMENTAL
Intervention: Intraperitoneal polyglactin mesh
Number of subjects: 288

Group type: COMPARATOR
Intervention: No intraperitoneal polyglactin mesh (control group)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 288
Study: 8062504

Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline infusion (control)
Number of subjects: 10
Study: 2663407

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paracetamol 650 mg
Number of subjects: 60
Study: 31067329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ASP1707 3 mg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ASP1707 5 mg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ASP1707 10 mg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ASP1707 15 mg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 540
Study: 29231604

Group type: EXPERIMENTAL
Intervention: Fire acupuncture with centro-square needles (FACSN)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Filiform needling (FN)
Number of subjects: 72
Study: 26383549

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification via the Approach Avoidance Task (implicit training to avoid gaming cues)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification via the Approach Avoidance Task (implicit training to approach gaming cues)
Number of subjects: 38
Study: 23199566

Group type: EXPERIMENTAL
Intervention: Cognitive remediation targeting basic cognitive processes (RECOS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive remediation targeting autobiographical memory (REMAu)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive remediation targeting metacognitive deficits (MBCT)
Number of subjects: 63
Study: 21946824

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study: 18424971

Group type: EXPERIMENTAL
Intervention: Coregistered ultrasound
Number of subjects: 35

Group type: COMPARATOR
Intervention: Preoperative MRI scans
Number of subjects: 35
Study: 16434517

Group type: EXPERIMENTAL
Intervention: CT-based navigation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imageless navigation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Freehand placement
Number of subjects: 90
Study: 12032174

Group type: EXPERIMENTAL
Intervention: Dietary long-chain n-3 PUFA (fish oil) for 6 weeks
Number of subjects: 51
Study: 10090350

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7594098

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 1473

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: early invasive management strategy
Number of subjects: 1473

Group type: COMPARATOR
Intervention: early conservative strategy
Number of subjects: 1473
Study: 2246790

Group type: EXPERIMENTAL
Intervention: Sex and aging workshop
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 20
Study: 7001687

Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride (100 mg initially followed by 100 mg twice daily for 10 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diethylcarbamazine citrate (DEC) at 126 mg per kg body-weight
Number of subjects: 78
Study: 6341623

Group type: EXPERIMENTAL
Intervention: Perioperative disinfection with chlorhexidine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intramuscular cephradine followed by oral nitrofurantoin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Chlorhexidine disinfection followed by oral nitrofurantoin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 65
Study: 31892215

Group type: EXPERIMENTAL
Intervention: DHA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA with oat beta-glucan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA with anthocyanins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29546292

Group type: EXPERIMENTAL
Intervention: Fish oil (1-g capsules containing ≥840 mg n-3 PUFAs as ethyl esters) with preoperative loading of 8-10 g over 2-5 days followed by 2 g/day until hospital discharge or postoperative day 10.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 26673130

Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Land-based exercise (LEx)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonexercise control (CON)
Number of subjects: 18
Study: 24952862

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15488
Study: 23019945

Group type: EXPERIMENTAL
Intervention: Jiangtang Xiaozhi Capsule (JTXZC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pioglitazone tablet
Number of subjects: 73
Study: 19696752

Group type: EXPERIMENTAL
Intervention: 1-year group intervention designed to promote autonomous self-regulation of body weight
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 1-year group intervention
Number of subjects: 225
Study: 17304654

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study: 15914135

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and Misoprostol 800 mcg vaginally
Number of subjects: 80
Study: 12074256

Group type: EXPERIMENTAL
Intervention: Almonds supplement (76 kJ daily) for six months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no almonds) during the first six months
Number of subjects: 81
Study: 10335000

Group type: EXPERIMENTAL
Intervention: Combined treatment (inhaled budesonide 200‐400 microg twice daily + terbutaline 500‐1000 microg four times daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Budesonide (200‐400 microg twice daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Terbutaline (500‐1000 microg four times daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 61
Study: 7769306

Group type: EXPERIMENTAL
Intervention: 480 mg TMP-SMZ once a day
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 960 mg TMP-SMZ once a day
Number of subjects: 260